Literature DB >> 3356019

Influence of whole body protein turnover rate on resting energy expenditure in patients with cancer.

K C Fearon1, D T Hansell, T Preston, J A Plumb, J Davies, D Shapiro, A Shenkin, K C Calman, H J Burns.   

Abstract

Whole body protein turnover and resting energy expenditure are measured simultaneously in weight stable and weight losing patients with lung (n = 22) or colorectal cancer (n = 38). These results were compared with those from weight stable and weight losing non-cancer controls (n = 22). Rates of whole body protein turnover were calculated from the plateau isotopic enrichment of urinary ammonia and urea following a primed, continuous, 24-h infusion of [15N]glycine. Resting energy expenditure was measured by indirect calorimetry. All groups of cancer patients had significantly elevated rates of whole body protein turnover (P less than 0.05) and synthesized, on average, 1.9 g/kg/day more protein compared with weight stable non-cancer controls. In contrast, the resting energy expenditure of cancer patients and controls was similar. Moreover, there was no correlation between individual rates of whole body protein turnover. Thus, although cancer patients had rates of whole body protein turnover which were 50-70% greater than controls, this did not result in a measurable increase in resting energy expenditure. The assumption that elevation of whole body protein turnover or resting energy expenditure causes weight loss in cancer patients must be an oversimplification. An acute phase protein response was observed in the majority of cancer patients. Although the presence of such an inflammatory response did not correlate with the rate of whole body protein turnover, the role of inflammatory mediators in the pathogenesis of disturbed protein metabolism in cancer patients merits further investigation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3356019

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  24 in total

Review 1.  Key determinants of energy expenditure in cancer and implications for clinical practice.

Authors:  S A Purcell; S A Elliott; V E Baracos; Q S C Chu; C M Prado
Journal:  Eur J Clin Nutr       Date:  2016-06-08       Impact factor: 4.016

Review 2.  Metabolic alteration in patients with cancer: nutritional implications.

Authors:  Y Sakurai; S Klein
Journal:  Surg Today       Date:  1998       Impact factor: 2.549

3.  Whole body protein metabolism in children with cancer.

Authors:  S E Daley; A D Pearson; A W Craft; J Kernahan; R A Wyllie; L Price; C Brock; C Hetherington; D Halliday; K Bartlett
Journal:  Arch Dis Child       Date:  1996-10       Impact factor: 3.791

Review 4.  Pathophysiology of cancer cachexia.

Authors:  U Keller
Journal:  Support Care Cancer       Date:  1993-11       Impact factor: 3.603

Review 5.  Computational modeling of cancer cachexia.

Authors:  Kevin D Hall; Vickie E Baracos
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2008-05       Impact factor: 4.294

6.  Elevated circulating interleukin-6 is associated with an acute-phase response but reduced fixed hepatic protein synthesis in patients with cancer.

Authors:  K C Fearon; D C McMillan; T Preston; F P Winstanley; A M Cruickshank; A Shenkin
Journal:  Ann Surg       Date:  1991-01       Impact factor: 12.969

7.  Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer.

Authors:  J S Falconer; K C Fearon; C E Plester; J A Ross; D C Carter
Journal:  Ann Surg       Date:  1994-04       Impact factor: 12.969

8.  Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response.

Authors:  Hongshan Li; Jingyu Yu; Chao Liu; Jiang Liu; Sriram Subramaniam; Hong Zhao; Gideon M Blumenthal; David C Turner; Claire Li; Malidi Ahamadi; Rik de Greef; Manash Chatterjee; Anna G Kondic; Julie A Stone; Brian P Booth; Patricia Keegan; Atiqur Rahman; Yaning Wang
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-06-01       Impact factor: 2.745

9.  Impact of Interleukin-6 on Drug-Metabolizing Enzymes and Transporters in Intestinal Cells.

Authors:  Florian Simon; Jessica Garcia; Laetitia Guyot; Jérôme Guitton; Gaelle Vilchez; Claire Bardel; Marylore Chenel; Michel Tod; Léa Payen
Journal:  AAPS J       Date:  2019-12-20       Impact factor: 4.009

10.  Pharmacometric Applications and Challenges in the Development of Therapeutic Antibodies in Immuno-Oncology.

Authors:  Lei Diao; Bernd Meibohm
Journal:  Curr Pharmacol Rep       Date:  2018-05-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.